No abstract

BackgroundWe describe the early experiences of adults with systemic rheumatic disease who received the COVID-19 vaccine.MethodsFrom 2 April to 30 April 2021, we conducted an online, international survey of adults with systemic rheumatic disease who received COVID-19 vaccination. We collected patient-reported data on clinician communication, beliefs and intent about discontinuing disease-modifying antirheumatic drugs (DMARDs) around the time of vaccination, and patient-reported adverse events after vaccination.ResultsWe analysed 2860 adults with systemic rheumatic diseases who received COVID-19 vaccination (mean age 55.3 years, 86.7% female, 86.3% white). Types of COVID-19 vaccines were Pfizer-BioNTech (53.2%), Oxford/AstraZeneca (22.6%), Moderna (21.3%), Janssen/Johnson & Johnson (1.7%) and others (1.2%). The most common rheumatic disease was rheumatoid arthritis (42.3%), and 81.2% of respondents were on a DMARD. The majority (81.9%) reported communicating with clinicians about vaccination. Most (66.9%) were willing to temporarily discontinue DMARDs to improve vaccine efficacy, although many (44.3%) were concerned about rheumatic disease flares. After vaccination, the most reported patient-reported adverse events were fatigue/somnolence (33.4%), headache (27.7%), muscle/joint pains (22.8%) and fever/chills (19.9%). Rheumatic disease flares that required medication changes occurred in 4.6%.ConclusionAmong adults with systemic rheumatic disease who received COVID-19 vaccination, patient-reported adverse events were typical of those reported in the general population. Most patients were willing to temporarily discontinue DMARDs to improve vaccine efficacy. The relatively low frequency of rheumatic disease flare requiring medications was reassuring.

No abstract

No abstract

Reinforcement Sensitivity Theory (RST; Gray, 1987; Gray & McNaughton, 2000) has proven to be a valuable tool for understanding psychopathy (e.g., Fowles, 1980, 1988; Newman & Malterer, 2009; Poythress, Edens, Landfield, Lilienfeld, Skeem, & Douglas, 2008). Recent research has linked two RST constructs, the Behavioral Inhibition System (BIS) and the Behavioral Activation System (BAS), to individuals with primary psychopathy and secondary psychopathy (Lykken, 1995; Newman, MacCoon, Vaughn, & Sadeh, 2005): Primary psychopaths manifest low BIS reactivity and secondary psychopaths manifest high BAS reactivity. In the present study, we examine the relationships between the BIS/BAS constructs and Factors 1 and 2 of the Psychopathy Checklist – Revised (PCL-R) in a sample of 472 incarcerated male offenders. Paralleling their relationships with primary and secondary psychopathy, the BIS/BAS constructs were differentially related to the two PCL-R factors. Specifically, the influence of the BIS was found to be more prominent than the influence of the BAS for Factor 1, and the influence of the BAS was more prominent than that of the BIS for Factor 2.